50
Participants
Start Date
August 3, 2022
Primary Completion Date
January 28, 2026
Study Completion Date
January 28, 2026
Darolutamide (Nubeqa, BAY1841788)
600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
COMPLETED
Dr. RML Hospital & PGIMER, New Delhi
WITHDRAWN
Dayanand Medical College & Hospital, Ludhiana
WITHDRAWN
Post Graduate Institute of Medical Education and Research, Chandigarh
RECRUITING
Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi
COMPLETED
Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur
COMPLETED
Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital), Nadiād
TERMINATED
Surat Institute of Digestive Sciences, Surat
RECRUITING
Tata Memorial Hospital, Mumbai
COMPLETED
Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati
COMPLETED
Apollo Research Foundation, Hyderabad
TERMINATED
HCG-City Cancer Centre, Vijayawada
TERMINATED
Victoria Hospital, Bangalore
COMPLETED
HCG Oncology Center, Bengaluru
TERMINATED
Fortis Hospital Bangalore, Bengaluru
WITHDRAWN
KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi
COMPLETED
Jawaharlal Institute Of Postgraduate Medical Education and R, Gorimedu
TERMINATED
Erode Cancer Centre, Erode
RECRUITING
MVR Cancer Centre and Research Institute, Vellalasseri
RECRUITING
Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram
RECRUITING
Netaji Subhas Chandra Bose Cancer Hospital, Kolkata
RECRUITING
All India Institute of Medical Sciences, Bhubaneswar
TERMINATED
MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad
TERMINATED
King George Hospital, Visakhapatnam
RECRUITING
Rajiv Gandhi Cancer Institute & Research Centre, New Delhi
RECRUITING
Amrita Institute of Medical Sciences, Kochi
Lead Sponsor
Bayer
INDUSTRY